Peritoneal Cancer

When added to chemotherapy, extending the duration of bevacizumab treatment from 15 to 30 months failed to improve progression-free survival or overall survival in patients with epithelial ovarian, fallopian tube or peritoneal cancer, according to a study presented at the ASCO Annual Meeting.

The FDA expanded the approval of niraparib for gynecologic cancers.